Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Beaudoin JJ, Bezençon J, Cao Y, Mizuno K, Roth SE, Brock WJ, Brouwer KLR.

Drug Metab Dispos. 2019 Feb;47(2):155-163. doi: 10.1124/dmd.118.083907. Epub 2018 Nov 30. Erratum in: Drug Metab Dispos. 2019 Mar;47(3):328.

PMID:
30504136
2.

Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.

Malinen MM, Ali I, Bezençon J, Beaudoin JJ, Brouwer KLR.

Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G597-G609. doi: 10.1152/ajpgi.00310.2017. Epub 2018 Feb 8.

PMID:
29420067
3.

FimH Antagonists: Phosphate Prodrugs Improve Oral Bioavailability.

Kleeb S, Jiang X, Frei P, Sigl A, Bezençon J, Bamberger K, Schwardt O, Ernst B.

J Med Chem. 2016 Apr 14;59(7):3163-82. doi: 10.1021/acs.jmedchem.5b01923. Epub 2016 Mar 18.

PMID:
26959338
4.

Enantiomeric cyclic peptides with different Caco-2 permeability suggest carrier-mediated transport.

Marelli UK, Bezençon J, Puig E, Ernst B, Kessler H.

Chemistry. 2015 May 26;21(22):8023-7. doi: 10.1002/chem.201501270. Epub 2015 Apr 27.

PMID:
25917866
5.

FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile.

Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, Lüdin N, Bezençon J, Schwardt O, Maier T, Ernst B.

J Med Chem. 2015 Mar 12;58(5):2221-39. doi: 10.1021/jm501524q. Epub 2015 Feb 20.

PMID:
25666045
6.

pKa determination by ¹H NMR spectroscopy - an old methodology revisited.

Bezençon J, Wittwer MB, Cutting B, Smieško M, Wagner B, Kansy M, Ernst B.

J Pharm Biomed Anal. 2014 May;93:147-55. doi: 10.1016/j.jpba.2013.12.014. Epub 2013 Dec 24.

PMID:
24462329
7.

FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.

Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lüthi C, Scharenberg M, Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.

J Med Chem. 2010 Dec 23;53(24):8627-41. doi: 10.1021/jm101011y. Epub 2010 Nov 24.

PMID:
21105658
8.

[Treating diabetic patients: various personal experiences].

Bezençon J.

Rev Med Suisse Romande. 1995 Sep;115(9):733-4. French. No abstract available.

PMID:
7481363
9.

[Automobile driving ability in diabetes mellitus].

Villiger U, Brückner R, Bezençon J.

Schweiz Rundsch Med Prax. 1986 May 20;75(21):635-8. German. No abstract available.

PMID:
3523677
10.

[Remarks on the alleged associations of a blue nevus and an ordinary intradermal nevus].

DELACRETAZ J, BEZENCON J.

Bull Soc Fr Dermatol Syphiligr. 1960 Jun-Jul;67:590-7. French. No abstract available.

PMID:
13721401

Supplemental Content

Loading ...
Support Center